source
- Novartis to buy Myricx Bio for $1.1 billion as Medicare proposes steep 340B cuts and other biotech policy updatesNovartis announced it will acquire UK‑based Myricx Bio for an upfront $1.1 billion, adding an antibody‑drug conjugate platform aimed at solid‑tumor cancers. The agreement also includes potential mi…
- Cancer and immune-focused biotech firms capture over $3.9 billion of H1 2026 venture capitalBioPharma Dive data show that cancer and immune disease biotech companies accounted for more than 40% of the biotech firms receiving venture funding in the first half of 2026. Of the roughly $9 bi…